Bioinvent International Ab · OMXSTO:BINV
Bioinvent International Ab — Investor Presentation (May 2020)
32 slides from Bioinvent International Ab's investor presentation, May 2020
Slide 1: Company Presentation May 2020
COMPANY PRESENTATION May 2020 1
Slide 2: Forward-Looking Statement
FORWARD-LOOKING STATEMENT This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in BioInvent International AB (“BioInvent”). Neither shall the presentation or any
Slide 3: Company Snapshot
COMPANY SNAPSHOT LEADING IMMUNO-ONCOLOGY ANTIBODY PLATFORM ▪ Advancing Cancer Immunotherapy by overcoming tumor resistance ✓ ▪ Lead product, BI-1206, currently in Phase I/II for relapsed or refractory indolent Non-Hodgkin Lymphoma (iNHL) patients with early results from Phase I open label study expe
Slide 4: Agenda
AGENDA Corporate overview Products & Markets Business development & Operations Summary Appendix 4
Slide 5: Pipeline – Multiple Value Drivers
PIPELINE – MULTIPLE VALUE DRIVERS Indication Program Discovery Preclinical Phase I Phase II Target: FcγRIIB NHL (MCL, MZL, iFL) BI-1206 / rituximab Solid cancer BI-1206/ pembrolizumab Solid cancer BI-1607 2021 Target: Tumor associated regulatory T cells (Tregs) Solid cancer BT-001/αCTLA4-VV 2020 Sol
Slide 6: F.I.R.S.T platform: a unique patient-centric platform for discovery
s F.I.R.S.T™- A UNIQUE PATIENT CENTRIC PLATFORM FOR DISCOVERY OF NOVEL ONCOLOGY TARGETS AND MABS BioInvent’s proprietary platform Fully integrated functional screening using proprietary models to identify relevant therapeutic targets Validated by: Fresh patient cells by: Clinically relevant targets
Slide 7: Upcoming News Flow
UPCOMING NEWS FLOW ✓ BI-1206 / pembrolizumab research and supply agreement with Merck (MSD) ✓ Pfizer selects second target for development from TAMs program collaboration Q4’19 ✓ BioInvent / Transgene announce promising preclinical data for BT-001 in solid tumors ✓ Promising preclinical data BI-1206
Slide 8: Agenda
AGENDA Corporate overview Products & Markets Business development & Operations Summary Appendix 8
Slide 9: BI-1206: Product Overview
BI-1206: PRODUCT OVERVIEW ▪ BI-1206 blocks the FcgRIIB receptor Description ▪ Blocking FcgRIIB allows the immune system to find and kill the tumor cell by enhancing the anti- tumoral activity of other antibodies such as rituximab or anti-PD-1 antibodies ▪ Initially in development for relapsed or ref
Slide 10: FcgRIIB – A single inhibitory antibody checkpoint
FcgRIIB – A SINGLE INHIBITORY ANTIBODY CHECKPOINT TO UNLOCK ANTI-CANCER IMMUNITY IN BOTH LIQUID AND SOLID TUMORS Antibody checkpoints T cell checkpoints Innate immunity Adaptive immunity Part of the immune system that kills tumor Activates Part of the immune system that eliminates the cells, but als
Slide 11: BI-1206 in Non-Hodgkin Lymphoma: Turbocharging Anti-CD20
BI-1206 IN NON-HODGKIN LYMPHOMA TURBOCHARGING ANTI-CD20 ▪ Rituximab (Roche’s Rituxan® or The immune cells fail to attack the tumor cell Mabthera®) is a monoclonal antibody that kills malignant B cells by binding to CD20 on the cell surface PRE BI-1206 ▪ The FcgRIIB-receptor functions to remove ritux
Slide 12: BI-1206 in Non-Hodgkin Lymphoma: Dual Impact on B Cells
BI-1206 IN NON-HODGKIN LYMPHOMA: DUAL IMPACT ON B CELLS BI-1206 BLOCKS RITUXIMAB INTERNALIZATION AND IMPROVES ITS ANTI-TUMOR ACTIVITY Human CD20 FcγRIIB double transgenic mice Humanized model of relapsed / refractory CLL1 B cell depletion in vivo BOOSTING RITUXIMAB’S EFFECT OVERCOMING RESISTANCE % o
Slide 13: BI-1206 in NHL: Value Proposition – Key Segments & Value Drivers
BI-1206 IN NON-HODGKIN LYMPHOMA: VALUE PROPOSTION – KEY SEGMENTS & VALUE DRIVERS KEY SUB-SEGMENTS OF NON-HODGKIN LYMPHOMA (NHL) BI-1206 value drivers ▪ Compelling scientific rationale in α-CD20 refractory B-cell lymphoma ▪ Chemo-free regimen ▪ Favorable safety profile MZL USD MCL ▪ Scalability of to
Slide 14: BI-1206 in Non-Hodgkin Lymphoma: Phase I/IIa Study
BI-1206 IN NON-HODGKIN LYMPHOMA: PHASE I/IIA STUDY STUDY OVERVIEW Current phase Start: Sep 2018 Part A Part B H2 2020 BI-1206 + RTX1 BI-1206 + RTX1 Patients with (375 mg/m2) (375 mg/m2) EARLY PHASE relapsed or 3+3 dose escalation Expansion phase I RESULTS refractory iNHL (n=9-12) IIa (n=12) (Expecte
Slide 15: Promising Preliminary Data from Phase I/IIa Study
BI-1206 IN NON-HODGKIN LYMPHOMA: PROMISING PRELIMINARY DATA FROM PHASE I/IIA STUDY • Preliminary data shows early signs of efficacy – In the 30 mg cohort: • 1 patient with FL remained on treatment for the full maintenance period (1 year) • 1 patient with blastoid Mantle Cell lymphoma, showed complet
Slide 16: BI-1206 Possesses Substantial Indication Growth Potential
BI-1206 POSSESSES SUBSTANTIAL INDICATION GROWTH POTENTIAL ESTABLISHING PROOF OF CONCEPT IN CERTAIN INDICATIONS CAN LEAD TO RAPID GROWTH IN TOTAL ADDRESSABLE MARKET Autoimmune diseases Other solid tumors NSCLC Metastatic melanoma NHL 16
Slide 17: BI-1206 in Solid Tumors: Phase I/IIa Study with Merck
BI-1206 IN SOLID TUMORS: PHASE I/IIA STUDY WITH MERCK STUDY OVERVIEW Current phase Start: Q1 2020 Part A Part B H2 2021 Patients with BI-1206 + If successful, the potential BI-1206 + solid tumors pembrolizumab pembrolizumab EARLY addressable market could be relapsed or sizable due to the high unmet
Slide 18: Tregs and TAMs in Solid Tumors: Product Overview
TREGS AND TAMS IN SOLID TUMORS: PRODUCT OVERVIEW ▪ Identifies and characterizes new targets and monoclonal antibodies to cancer- associated Regulatory T cell (Treg) Description ▪ Discovers novel targets and therapeutic antibodies that may reverse or reduce tumor- associated myeloid cells (TAMs), whi
Slide 19: Targeting Tregs and TAMs to Mitigate Immune Suppression
TARGETING TREGS AND TAMS TO MITIGATE IMMUNE SUPPRESSION ▪ Regulatory T cells (Tregs) can Developing antibodies that act on Tregs via novel or validated targets substantially inhibit immune responses, enabling tumor cells to 1 2 3 TARGETING TREGS escape detection ▪ BioInvent is utilizing its F.I.R.S.
Slide 20: BT-001 in Solid Tumors: Product Overview
BT-001 IN SOLID TUMORS: PRODUCT OVERVIEW ▪ Collaboration with Transgene to co-develop oncolytic virus candidates encoding an anti- CTLA-4 antibody sequence, potentially with additional transgenes, aimed at treating Description solid tumors ▪ The collaboration costs and profit are shared 50/50 ▪ Buil
Slide 21: BT-001: mAbs + Oncolytic Virus to Target Solid Tumors
BT-001: MABS + ONCOLYTIC VIRUS TO TARGET SOLID TUMORS 50/50 PARTNERSHIP WITH TRANSGENE TO DEVELOP NEXT GENERATION ONCOLYTIC VIRUSES mAbs and oncolytic virus attack the solid tumor together ABOUT THE COLLABORATION BioInvent’s CTLA-4 mAb ▪ BioInvent and Transgene collaborate to co-develop oncolytic vi
Slide 22: Agenda
AGENDA Corporate overview Products & Markets Business development & Operations Summary Appendix 22
Slide 23: Partnerships & Collaborations
PARTNERSHIPS & COLLABORATIONS Active partnerships & collaborations ▪ Partners since December 2016, first target discovered in July 2019, second target in December 2019 ▪ BioInvent is eligible for potential future development milestones in excess of USD 500 million as well as double digit royalties ▪
Slide 24: Proprietary Manufacturing Platform Since 1988
PROPRIETARY MANUFACTURING PLATFORM SINCE 1988 BioInvent has ample experience with in-house production of antibodies ensuring that no delays will occur when scaling up production to meet the demand for the various clinical trials ▪ Supports fast and flexible production of proprietary programs ▪ Appro
Slide 25: Agenda
AGENDA Corporate overview Products & Markets Business development & Operations Summary Appendix 25
Slide 26: Upcoming News Flow
UPCOMING NEWS FLOW ✓ BI-1206 / pembrolizumab research and supply agreement with Merck (MSD) ✓ Pfizer selects second target for development from TAMs program collaboration Q4’19 ✓ BioInvent / Transgene announce promising preclinical data for BT-001 in solid tumors ✓ Promising preclinical data BI-1206
Slide 27: Data Available at Confidential Level
DATA AVAILABLE AT CONFIDENTIAL LEVEL ❑ FcgRIIB confers local resistance in the tumor microenvironment to antibody-based therapy, ANTI-FcgRIIB including anti-PD1, anti-PDL1 and anti-CTLA4 (and many others) BI-1206 & BI-1607 ❑ Detailed efficacy and MoA data evaluating BI-1206 and BI-1607 differential
Slide 28: Company Snapshot
COMPANY SNAPSHOT LEADING IMMUNO-ONCOLOGY ANTIBODY PLATFORM ▪ Advancing Cancer Immunotherapy by overcoming tumor resistance ✓ ▪ Lead product, BI-1206, currently in Phase I/II for relapsed or refractory indolent Non-Hodgkin Lymphoma (iNHL) patients with early results from Phase I open label study expe
Slide 29: Company Presentation
COMPANY PRESENTATION May 2020 29
Slide 30: Agenda
AGENDA Corporate overview Products & Markets Business development & Operations Summary Appendix 30
Slide 31: Management Team
MANAGEMENT TEAM Martin Welschof Björn Frendéus Andres McAllister Chief Executive Officer Chief Scientific Officer Chief Medical Officer Holdings: 125,000 shares Holdings: 483,083 shares; 270,258 options Holdings: 91,656 options Ph.D. (Dr.rer.nat.) in recombinant antibody technology. Born 1961. Docto
Slide 32: Board of Directors
BOARD OF DIRECTORS Leonard Kruimer An van Es Johansson Dharminder Chahal Chairman Board member Board member Holdings: - 240,080 Holdings: 183,584 shares Holdings: 2,802,661 shares MBA, CPA in the New York State. Born 1958. Resident of the M.D. Born 1960. Lives in Stockholm, Sweden. Previously differ
BioInvent International — Investor Presentation (May 2020) on 6ix